Antibe Therapeutics Inc.
1063 King St. West
Suite 210
Hamilton
Ontario
L8S 4S3
Canada
Tel: 905-515-6132
Fax: 905-528-9862
Website: http://www.antibe-therapeutics.com/
200 articles about Antibe Therapeutics Inc.
-
Antibe Provides Development Update for Otenaproxesul
10/12/2022
Antibe Therapeutics Inc. is pleased to announce a major advance in otenaproxesul’s formulation that promises to increase its therapeutic benefit and commercial potential. Accordingly, the Company has filed a patent application that strengthens the drug’s IP protection to 2042.
-
Antibe Announces Results of 2022 Annual Meeting
9/9/2022
Antibe Therapeutics Inc. is pleased to announce the results of its annual meeting of shareholders held earlier.
-
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
9/6/2022
Antibe Therapeutics Inc., a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute pain efficacy, to be delivered at the PAINWeek National Conference taking place on September 6 - 9 in Las Vegas.
-
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
8/15/2022
Antibe Therapeutics Inc has filed its financial and operating results for the fiscal quarter ended June 30, 2022.
-
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
6/30/2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2022.
-
Antibe Therapeutics Announces Amendment to Warrant Terms
6/15/2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the " Company "), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the “ Warrant Extension ”) and amending the exercise price (the “ Amended Exercise Price ”) of 3,117,957 common share purchase warrants (“ Warrants ”) of the Company.
-
Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
5/25/2022
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the appointment of Robert E. Hoffman, a Director of Antibe, as the new Chair of its Board of Directors.
-
Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
5/2/2022
Antibe Therapeutics Inc. is pleased to announce the signing of a binding agreement to sell its Citagenix Inc. subsidiary to HANSAmed Limited.
-
Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
4/25/2022
Antibe Therapeutics Inc. today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022.
-
Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
2/14/2022
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended December 31, 2021.
-
Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results
11/16/2021
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended September 30, 2021.
-
Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program
11/1/2021
Antibe Therapeutics Inc. is pleased to provide further detail on otenaproxesul’s development plan for acute pain indications.
-
Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
10/14/2021
Antibe Therapeutics Inc. is pleased to provide an update following a full scientific and strategic review involving external experts and key opinion leaders.
-
Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13 - 15.
-
Antibe Therapeutics Announces Results of 2021 Annual Meeting
8/19/2021
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today.
-
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
8/17/2021
Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal quarter ended June 30, 2021.
-
Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
8/9/2021
Antibe Therapeutics Inc. today announced its participation in the Canaccord Genuity 41st Annual Growth Conference being held virtually on August 10 - 12.
-
Antibe Therapeutics Provides Clinical Update for Otenaproxesul
8/3/2021
Antibe Therapeutics Inc. has placed its absorption, metabolism and excretion (“AME”) study of otenaproxesul on a required pause because a pre-specified safety threshold was exceeded.
-
Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights
6/28/2021
Antibe Therapeutics Inc., a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, filed its financial and operating results for the fiscal year ended March 31, 2021.
-
Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion
6/25/2021
Antibe Therapeutics Inc., a clinical-stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to target inflammation in a wide range of health conditions, announced a strategic collaboration with Dalriada Drug Discovery to develop new drug candidates and fortify Antibe’s intellectual property position for its current pipeline.